Why NovoCure Stock Dived by 13% This Week
A series of C-suite changes negatively affected the share price of cancer-focused biotech NovoCure (NASDAQ: NVCR) across the holiday-shortened trading week. When the smoke cleared, the company's stock had eroded by slightly over 13% over the Tuesday to Friday stretch, according to data compiled by S&P Global Market Intelligence.
On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be replaced by the biotech company's current CFO, Ashley Cordova.
Following the transition, Danziger will not be a stranger to NovoCure. He will serve as senior advisor to the company into early 2026, and continue to occupy a seat on its board of directors.
Source Fool.com
